openPR Logo
Press release

Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022 | Amcyte Pharma Inc, AnaMar AB, AnaptysBio Inc, ASC Therapeutics Inc

12-27-2022 06:06 AM CET | Health & Medicine

Press release from: Global Insight Services

Graft Versus Host Disease (GVHD)

Graft Versus Host Disease (GVHD)

Global Insight Services have recently published a report on Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.

Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient's body cell. GvHD is of two types: acute GvHD - which develops within 100 days of transplantation and chronic GvHD - which develops after 100 days of transplantation.

GvHD occurs after the bone marrow transplants and stem cell transplants. Following are the other occurrences of GvHD - allogenic bone transplantation, solid organs that are rich in lymphoid cells and un-irradiated blood.

View Detailed Report Description : https://www.globalinsightservices.com/reports/graft-versus-host-disease-gvhd-drug-pipeline-landscape-2022/

GvHD is diagnosed through imaging - X-ray abdomen, CT scan abdomen and chest, PET scan and MRI. Other diagnosis involves liver function tests, liver biopsy and capsule endoscopy.

Treatments depends on the severity of symptoms and organs involvement. Corticosteroids are commonly used treatment. Topical steroids are used to control local symptoms. Cyclosporine is added to the treatment regimen of chronic GvHD. Prophylactic treatment is recommended.

There are many other trials ongoing in GVHD Drug Development. These trials are studying a variety of new and existing drugs, as well as new ways to use existing drugs.

Report Highlights

Global Insight Service's, Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022 report provides an overview of the Graft Versus Host Disease (GVHD) pipeline drugs. This report covers detailed insights on Graft Versus Host Disease (GVHD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Graft Versus Host Disease (GVHD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Request Sample Report : https://www.globalinsightservices.com/request-sample/GIS31106

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Get a 50% Off on Purchase of this Report Use Code (GIS2022SUP50) : https://www.globalinsightservices.com/checkout/single_user/GIS31106

Key Players

9 Meters Biopharma Inc
Abbisko Cayman Limited
Accro BioScience (Suzhou) Co Ltd
Actitrexx GmbH
Adienne Pharma & Biotech SA
Alphamab Oncology
AltruBio Inc
Amcyte Pharma Inc
AnaMar AB
AnaptysBio Inc
ASC Therapeutics Inc
AstraZeneca Plc
Avalon GloboCare Corp
Biogen Inc
BioIncept LLC

Request For Customization : https://www.globalinsightservices.com/request-customization/GIS31106

Reasons to buy Graft Versus Host Disease (GVHD) Report:

• Develop comprehensive understanding of market landscape - industry structure, value-chain, key players, trends, drivers, and challenges
• Drive revenue and market-entry strategy by gaining insights into which segments and geographies are largest and likely to grow fastest
• Formulate sales and marketing strategies by gaining understanding of competitors, their positioning, and strengths & weaknesses
• Develop business and M&A strategies through understanding of latest trends and emerging players in the market
• Refine your business plans by understanding impact of disruptions such as Covid-19 and Russia-Ukraine conflict on the market

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022 | Amcyte Pharma Inc, AnaMar AB, AnaptysBio Inc, ASC Therapeutics Inc here

News-ID: 2863476 • Views:

More Releases from Global Insight Services

Public Key Infrastructure (PKI) Market to Reach $12.6 Billion by 2034 With 9.9% CAGR Growth
Public Key Infrastructure (PKI) Market to Reach $12.6 Billion by 2034 With 9.9% …
The Public Key Infrastructure (PKI) Market plays a critical role in the global cybersecurity landscape, enabling organizations to secure electronic communications and digital transactions. By providing a framework for encryption, authentication, and digital certificates, PKI ensures trust, confidentiality, and data integrity across industries. From banking and government services to healthcare and manufacturing, PKI has become essential in a world increasingly reliant on digital technologies. As enterprises accelerate digital transformation, the
Fish Sauce Market Grows From $2.2 Billion in 2024 Amid Rising Demand for Authentic Asian Flavors
Fish Sauce Market Grows From $2.2 Billion in 2024 Amid Rising Demand for Authent …
The Fish Sauce Market has long been an integral part of Asian culinary traditions, particularly in countries such as Vietnam and Thailand. Made from fermented fish and salt, this flavorful condiment has been a staple for centuries, adding depth and umami to countless dishes. Today, the Fish Sauce Market is expanding far beyond its roots, finding its way into kitchens across North America, Europe, and beyond. With the rising global
Breath Analyzer Market Is Anticipated To Expand From $4.1 Billion In 2024 To $9.8 Billion By 2034
Breath Analyzer Market Is Anticipated To Expand From $4.1 Billion In 2024 To $9. …
Market Overview The Breath Analyzer Market is gaining remarkable traction worldwide as demand for alcohol detection and health monitoring tools continues to rise. These devices, designed to measure blood alcohol content (BAC) through breath samples, have become indispensable in law enforcement, healthcare, and workplace safety. The market is projected to expand from $4.1 billion in 2024 to $9.8 billion by 2034, growing at a CAGR of 9.1%. This growth is fueled
Web Hosting Services Market Is Anticipated To Expand From $83.99 Billion In 2024 To $267.10 Billion By 2034
Web Hosting Services Market Is Anticipated To Expand From $83.99 Billion In 2024 …
Market Overview The Web Hosting Services Market is evolving rapidly as businesses and individuals continue to strengthen their online presence. Hosting services act as the backbone of the digital economy, providing the infrastructure that powers websites, e-commerce platforms, and digital applications. The industry covers a wide range of offerings, including shared hosting, dedicated hosting, virtual private servers (VPS), and cloud hosting. Each solution caters to different customer needs, from small businesses

All 5 Releases


More Releases for GVHD

Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022
Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient's body cell. GvHD is of two types: acute GvHD - which develops within 100 days of transplantation and chronic GvHD - which develops after 100
Graft Versus Host Disease (GvHD) Market Expected to Expand at a Steady 2022-2028 …
Coherent Market Insights have added a new research study on Title Graft Versus Host Disease (GvHD) Market, Global Outlook and Forecast 2022-2028 with detailed information & Key Players Such as Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd. The Study provides in-depth comprehensive analysis includes Clear Market definitions, classifications, manufacturing processes, cost structures, development policies and plans. The
Graft Versus Host Disease GvHD Treatment Market Investment Research Report 2016- …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain
Graft Versus Host Disease GvHD Treatment Market Revenue and Value Chain 2016-202 …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape. Graft-versus-host disease (GVHD) is a complication that can occur after
Graft Versus Host Disease (GvHD) Market - Global Industry Analysis 2024
During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a